Literature DB >> 19693669

Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.

B Weiss1, O Lebowitz, H H Fidder, I Maza, A Levine, R Shaoul, S Reif, Y Bujanover, A Karban.   

Abstract

PURPOSE: Factors influencing response to medications in Crohn's disease (CD) patients are not fully understood. We aimed to evaluate the relationships between NOD2/CARD15 mutations, disease phenotype and age of CD diagnosis and response to medical treatment with systemic steroids, azathioprine (AZA) or 6-mercaptopurine (6-MP), and infliximab.
METHODS: A retrospective medical records analysis was made of patients previously tested for the CD-associated NOD2/CARD15 mutations. Harvey- Bradshaw score was used to assess remission or response to therapy.
RESULTS: CD-associated NOD2/CARD15 mutations were not related to the rate of steroids dependency or clinical response to AZA/6-MP and infliximab. Steroid dependency was associated with colonic involvement. Thirty-three of 127 (26%) patients with colonic disease were steroid dependent, compared with 7/72 (9.7%) patients with isolated small bowel disease (ISBD), (p = 0.009). ISBD was mildly associated with a better remission/response to AZA/6-MP treatment. Disease behavior and age of diagnosis were not related to response to therapy.
CONCLUSIONS: Response to treatment with systemic steroids, AZA/6-MP and infliximab are not related to NOD2/CARD15 mutations, age of diagnosis and disease behavior. Patients with colonic disease have higher rates of steroid dependency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693669     DOI: 10.1007/s10620-009-0936-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

3.  Crohn's disease: influence of age at diagnosis on site and clinical type of disease.

Authors:  J M Polito; B Childs; E D Mellits; A Z Tokayer; M L Harris; T M Bayless
Journal:  Gastroenterology       Date:  1996-09       Impact factor: 22.682

4.  High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance.

Authors:  R Towers; T Naftali; G Gabay; M Carlebach; A Klein; B Novis
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

5.  Frequency of glucocorticoid resistance and dependency in Crohn's disease.

Authors:  P Munkholm; E Langholz; M Davidsen; V Binder
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

Authors:  Jeffrey Hyams; Wallace Crandall; Subra Kugathasan; Anne Griffiths; Allan Olson; Jewel Johanns; Grace Liu; Suzanne Travers; Robert Heuschkel; James Markowitz; Stanley Cohen; Harland Winter; Gigi Veereman-Wauters; George Ferry; Robert Baldassano
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

8.  Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.

Authors:  James Markowitz; Jeffrey Hyams; David Mack; Neal Leleiko; Jonathan Evans; Subra Kugathasan; Marian Pfefferkorn; Adam Mezoff; Joel Rosh; Vasundhara Tolia; Anthony Otley; Anne Griffiths; M Susan Moyer; Maria Oliva-Hemker; Robert Wyllie; Robert Rothbaum; Athos Bousvaros; J Fernando Del Rosario; Sandra Hale; Trudy Lerer
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-24       Impact factor: 11.382

9.  IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

Authors:  Elena Urcelay; Juan-Luis Mendoza; Alfonso Martinez; Laura Fernandez; Carlos Taxonera; Manuel Diaz-Rubio; Emilio-G de la Concha
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

10.  Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients.

Authors:  Herma H Fidder; Sylviane Olschwang; Benjamin Avidan; Habib Zouali; Alon Lang; Eytan Bardan; Orit Picard; Simon Bar-Meir; Jean Frederic Colombel; Yehuda Chowers
Journal:  Am J Med Genet A       Date:  2003-09-01       Impact factor: 2.802

View more
  5 in total

Review 1.  Role of genetics in the diagnosis and prognosis of Crohn's disease.

Authors:  Epameinondas V Tsianos; Konstantinos H Katsanos; Vasileios E Tsianos
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

Review 2.  Role of genetics in the diagnosis and prognosis of Crohn's disease.

Authors:  Epameinondas V Tsianos; Konstantinos H Katsanos; Vasileios E Tsianos
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

3.  NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy.

Authors:  Jan Hendrik Niess; Jochen Klaus; Johannes Stephani; Carolin Pflüger; Nadine Degenkolb; Ulrike Spaniol; Benjamin Mayer; Georgia Lahr; Georg B T von Boyen
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

4.  Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn's Disease-A Systematic Review and Gene Ontology Analysis.

Authors:  Boris Gole; Uroš Potočnik
Journal:  Cells       Date:  2019-05-28       Impact factor: 6.600

5.  Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease.

Authors:  Carsten Posovszky; Veronika Pfalzer; Georgia Lahr; Jan Hendrik Niess; Jochen Klaus; Benjamin Mayer; Klaus-Michael Debatin; Georg B T von Boyen
Journal:  BMC Gastroenterol       Date:  2013-05-02       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.